We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Recro Pharma Inc (REPH) USD0.01

Sell:$1.45 Buy:$1.67 Change: $0.03 (1.95%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Sell:$1.45
Buy:$1.67
Change: $0.03 (1.95%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
Sell:$1.45
Buy:$1.67
Change: $0.03 (1.95%)
Market closed |  Prices as at close on 30 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Recro Pharma, Inc. is a contract development and manufacturing organization (CDMO). The Company is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. It also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. It operates in one segment. It provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The Company develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.

Contact details

Address:
1 E. UWCHLAN AVE, SUITE 112
EXTON
19341
United States
Telephone:
+1 (770) 5348239
Website:
https://ir.recropharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
REPH
ISIN:
US75629F1093
Market cap:
$72.72 million
Shares in issue:
46.61 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wayne Weisman
    Independent Chairman of the Board
  • J. David Enloe
    President, Chief Executive Officer, Director
  • Ryan Lake
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.